Beijing-based QS Medical Technology Co. Ltd (QS) has developed a new needle-free injection technology, using a medical-grade polycarbonate from Covestro.
The technology, which has been designed for patients with diabetes, delivers drug safely and effectively through injecting it at high pressure under the skin surface.
“We are focused on developing innovative medical products to make life a little easier, safer and more comfortable for millions of patients in China and around the world,” said Justin Zhang, founder and general manager for QS.
The company partnered with Leverkusen, Germany-based materials company Covestro for the production of the devices in a bid to meet the needs of a growing number of patients with diabetes.
QS is using Covestro’s medical grade polycarbonate Makrolon Rx1805 in the production of the insulin-delivery interface and for moulding the ampoules containing the medication for needle-free syringe products.
Makrolon, according to Covestro, has “excellent properties of durability, processability, safety and design flexibility, which meet the stringent requirements of a wide variety of medical products.”
The material is resistant to cracking against lipids, radiation sterilisation and impact, while being highly efficient during the moulding of the ampoule bottles, Covestro said.